Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Durect ( (DRRX) ) has issued an announcement.
On September 11, 2025, DURECT Corporation completed a merger with Bausch Health Americas, Inc., resulting in DURECT becoming an indirect wholly owned subsidiary of Bausch Health. The merger was executed without a stockholder vote, and as part of the transaction, DURECT’s shares were delisted from Nasdaq. The merger led to significant changes in the company’s board and corporate structure, with the directors of the merger subsidiary taking over as directors of the surviving corporation.
The most recent analyst rating on (DRRX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Durect stock, see the DRRX Stock Forecast page.
Spark’s Take on DRRX Stock
According to Spark, TipRanks’ AI Analyst, DRRX is a Neutral.
Durect’s overall stock score reflects significant financial challenges and unattractive valuation. The merger with Bausch Health offers potential strategic benefits, but the risk of Nasdaq delisting remains a major concern. Mixed technical indicators further complicate the investment outlook.
To see Spark’s full report on DRRX stock, click here.
More about Durect
Average Trading Volume: 1,193,411
Technical Sentiment Signal: Buy
Current Market Cap: $59.31M
See more data about DRRX stock on TipRanks’ Stock Analysis page.